MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'biotech cancer'. Sat, 03 Sep 2011 02:49:10 +0100 http://www.medworm.com/index.php?rid=5139658&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F008243.html Longer life thru genetic engineering. (PHILADELPHIA) -- In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells. The protocol, which involves removing patients' cells and modifying them in Penn's vaccine production facility, then infusing the new cells back into the patient's body following chemotherapy, provides a tumor-attack roadmap for the treatment of other cancers including those of the lung and ovaries and myeloma and melanoma. The findings, published simultaneously today in the New England... FuturePundit blogs http://www.medworm.com/rss/comments.php?id=5139658 Mon, 15 Aug 2011 23:00:00 +0100 5139658 http://www.medworm.com/index.php?rid=5050475&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F008183.html Sam W. Lee and Anna Mandinova of Massachusetts General Hospital have accidentally discovered a compound that kills cancer cells by suppressing enzymes that detoxify free radicals. A cancer cell may seem out of control, growing wildly and breaking all the rules of orderly cell life and death. But amid the seeming chaos there is a balance between a cancer cell's revved-up metabolism and skyrocketing levels of cellular stress. Just as a cancer cell depends on a hyperactive metabolism to fuel its rapid growth, it also depends on anti-oxidative enzymes to quench potentially toxic reactive oxygen species (ROS) generated by such high metabolic demand. Scientists at the Broad Institute and Massachusetts General Hospital (MGH) have discovered a novel compound that blocks... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=5050475 Sat, 16 Jul 2011 23:00:00 +0100 5050475 http://www.medworm.com/index.php?rid=4813218&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F008076.html One problem with gene therapy is how to deliver the genes. The immune system will react to gene carrier packages, the liver potentially could filter out the gene therapy packages, and genes usually should go to only a small number of cell types and organs Packaging gene therapy into microbubbles enables better control and success for delivering gene therapy into cancer cells in prostates. Richmond, Va. (May 10, 2011) – Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology. The research was conducted by scientists at Virginia Commonwealth University Massey Cancer Center, VCU Institute of Molecular... (Sourc... FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4813218 Wed, 11 May 2011 23:00:00 +0100 4813218 http://www.medworm.com/index.php?rid=4349483&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007827.html Whereas in 2010 in the United States cancer treatment cost about $124.6 billion in 10 years cancer is projected to cost somewhere between $159 billion to $207 billion per year. If cancer incidence and survival rates and costs remain stable and the U.S. population ages at the rate predicted by the U.S. Census Bureau, direct cancer care expenditures would reach $158 billion in 2020, the report said. But will survival rates remain stable? When do cancer treatments finally start making a big impact? When do cancer treatments become less damaging to the rest of the body while also becoming much more able to kill cancer cells? However, the researchers also did additional analyses to account for changes in cancer incidence... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4349483 Fri, 14 Jan 2011 00:00:00 +0100 4349483 http://www.medworm.com/index.php?rid=4343334&cid=t_112091_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FCgLvWskDCNk%2F Hello, everyone, and top of the morning to you. A steely, wintry sky hovers over the Pharmalot corporate campus this morning, where we are enduring the usual routine of hustling short people to this or that school house. As we cope - where is that cup of stimulation? - please join us in perusing the news of the world. Meanwhile, feel free to pass along interesting tidbits. Have a good one… AstraZeneca And Cancer Charity Strike Drug Testing Deal (Bloomberg News) FDA Warns Of Acetaminophen Risks Of Liver Toxicity (Drug Store News) Drug Shortages Persist With No End In Sight (Daily Finance) Biotechs And Generics Spar Over Biologic Exclusivity (The Wall Street Journal) FDA Says Sanofi-Aventis’ Lantus Link To Cancer Is Unclear (Reuters) US Cancer Costs Are Expected To Soar (Los Ange... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4343334 Thu, 13 Jan 2011 13:02:18 +0100 4343334 http://www.medworm.com/index.php?rid=4309570&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007800.html Johnson & Johnson is teaming up with Massachusetts General Hospital to try to bring to market a microchip that can detect cancer at very low concentrations in the blood. Researchers at Massachusetts General Hospital have already developed a prototype of a microchip that can detect tumor cells at extremely low levels in the bloodstream. The effort to be announced today intends to draw on the expertise of scientists familiar with how to bring such technologies to patients and doctors. The hope is to lower costs below the current $500 per chip. A big cost reduction seems a reasonable expectation because small things like computer chips get cheaper every year. Biotechnology is increasingly following the pattern of the semiconductor computer industry... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4309570 Tue, 04 Jan 2011 00:00:00 +0100 4309570 http://www.medworm.com/index.php?rid=4207275&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007697.html Initiating an immune response prevented recurrence of a colon cancer that had metastasized to the liver. "The results of the study suggest a new way to approach cancer treatment," said Richard Barth Jr., MD, Chief of General Surgery at Dartmouth-Hitchcock Medical Center and a member of the Gastrointestinal Clinical Oncology Group at Dartmouth-Hitchcock Norris Cotton Cancer Center, who is the study's principal investigator. "Basically, we've worked out a way to use dendritic cells, which initiate immune responses, to induce an antitumor response." So the cancer had already mutated the ability to metastatize and had created a secondary tumor in the liver big enough to identify and remove. In these cases the odds are very high the tumor has landed in... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4207275 Sun, 28 Nov 2010 00:00:00 +0100 4207275 http://www.medworm.com/index.php?rid=4183265&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007663.html Complete melanoma remission in mice was achieved with gene therapy to turn up the immune system against the cancer. INDIANAPOLIS – A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation. The online version is now available. The cloned gene came from a patient with melanoma and the gene amped up immune response to melanoma. Indiana University School of Medicine researchers used a modified lentivirus to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic stem cells of mice. Hematopoietic stem cells are the bone marrow... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4183265 Fri, 19 Nov 2010 00:00:00 +0100 4183265 http://www.medworm.com/index.php?rid=4139199&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007624.html Stromal cells in tumors excrete a protein that tells the immune system not to attack cancer cells. A way to suppress that protein would open up tumors to immune attack. Researchers at the University of Cambridge hope to revolutionise cancer therapy after discovering one of the reasons why many previous attempts to harness the immune system to treat cancerous tumours have failed. New research, published today in the journal Science, reveals that a type of stromal cell found in many cancers which expresses fibroblast activation protein alpha (FAP), plays a major role in suppressing the immune response in cancerous tumours – thereby restricting the use of vaccines and other therapies which rely on the body's immune system to work. They... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4139199 Fri, 05 Nov 2010 00:00:00 +0100 4139199 http://www.medworm.com/index.php?rid=4121843&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007611.html One of the biggest benefits from the continuing plunge in DNA testing costs is going to be earlier diagnosis of cancers. One DNA test under development for colon cancer detection will be usable at home. David Ahlquist, M.D., professor of medicine and a consultant in gastroenterology at the Mayo Clinic in Rochester, said much of that low rate may be due to inconveniences associated with conventional approaches. "There is definitely an incentive and legitimate justification to be designing a screening approach that is user friendly, affordable and has the ability to detect pre-cancers," said Ahlquist. "The noninvasive stool DNA test we have developed is simple for patients, involves no diet or medication restriction, no unpleasant bowel preparation, and no lost... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4121843 Sun, 31 Oct 2010 00:00:00 +0100 4121843 http://www.medworm.com/index.php?rid=4118863&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2FTMNo1cXBBp4%2F Wall Street Journal health blogger Katherine Hobson will take questions from readers in a live chat on Monday, Nov. 1 about the TEDMED conference in San Diego.  Ask your questions now. (Source: WSJ.com: Health Blog) WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=4118863 Fri, 29 Oct 2010 18:27:37 +0100 4118863 http://www.medworm.com/index.php?rid=4118830&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007604.html Pancreatic cancer has long been viewed as a rapidly developing cancer because life expectancy from day of diagnosis is usually less than 3 years with 95% of those diagnosed dead within 5 years. But use of DNA sequencing technology has enabled researchers Christine Iacobuzio-Donahue, Bert Vogelstein, and evolutionary biologist Martin Nowak to determine that most pancreatic cancers almost 20 years to develop enough to kill their victims. Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news: an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=4118830 Tue, 26 Oct 2010 23:00:00 +0100 4118830 http://www.medworm.com/index.php?rid=3907560&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007442.html Malignant melanoma is the third larger cancer killer. A drug aimed at a genetic mutation common with malignant melanoma reduces tumors in most patients who had the mutation. An experimental drug designed to block the effects of a genetic mutation often found in patients with malignant melanoma, a deadly cancer with few existing treatments, significantly shrank tumors in about 80 percent of those who carried the mutation. Click thru and read all the details. A small percentage of the patients experienced disappearance of tumours. But do not expect it at a doctor's office any time soon. Further studies are needed before the drug can be approved by the FDA. I find this infuriating. Once you've been given a death sentence... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=3907560 Thu, 26 Aug 2010 23:00:00 +0100 3907560 http://www.medworm.com/index.php?rid=3750015&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007340.html Some day you'll be able to get your immune cells reprogrammed to go on hunter killer attack missions against tumors. Researchers at UCLA’s Jonsson Comprehensive Cancer Center created a large, well armed battalion of tumor-seeking immune system cells and watched, in real time using Positron Emission Tomography (PET), as the special forces traveled throughout the body to locate and attack dangerous melanomas. But for now this sort of thing only gets done for those tricky lab mice who have done such a great job of convincing researchers into developing medical treatments for them first. If I had terminal cancer and a large sum of money I'd hire medical researchers to do this to my own immune system. The gene therapy... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=3750015 Mon, 12 Jul 2010 23:00:00 +0100 3750015 http://www.medworm.com/index.php?rid=3625455&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007224.html Nanosponges carrying cancer chemo-therapy drugs selectively target cancer cells in mice. When loaded with an anticancer drug, a delivery system based on a novel material called nanosponge is three to five times more effective at reducing tumor growth than direct injection. That is the conclusion of a paper published in the June 1 issue of the journal Cancer Research. "Effective targeted drug delivery systems have been a dream for a long time now but it has been largely frustrated by the complex chemistry that is involved," says Eva Harth, assistant professor of chemistry at Vanderbilt, who developed the nanosponge delivery system. "We have taken a significant step toward overcoming these obstacles." So far these nanosponges have only been tested in... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=3625455 Tue, 01 Jun 2010 23:00:00 +0100 3625455 http://www.medworm.com/index.php?rid=3390731&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007042.html A phase I clinical trial shows promise for RNA interference as an anti-cancer therapy. PASADENA, Calif.—A California Institute of Technology (Caltech)-led team of researchers and clinicians has published the first proof that a targeted nanoparticle—used as an experimental therapeutic and injected directly into a patient's bloodstream—can traffic into tumors, deliver double-stranded small interfering RNAs (siRNAs), and turn off an important cancer gene using a mechanism known as RNA interference (RNAi). Moreover, the team provided the first demonstration that this new type of therapy, infused into the bloodstream, can make its way to human tumors in a dose-dependent fashion—i.e., a higher number of nanoparticles sent into the body leads to a higher number of nanoparticles in the tumor c... FuturePundit blogs http://www.medworm.com/rss/comments.php?id=3390731 Sun, 21 Mar 2010 00:00:00 +0100 3390731 http://www.medworm.com/index.php?rid=3346426&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F007000.html For a long time nanotechnology was one of those technologies that lay only in our future. It is starting to show up in our present. Cornell researchers have attached antibodies to nanoparticles to attack colorectal cancer cells. ITHACA, N.Y. - Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone. Led by Carl Batt, the Liberty Hyde Bailey Professor of Food Science, the researchers synthesized nanoparticles – shaped something like a dumbbell – made of gold sandwiched between two pieces of iron oxide. They then attached antibodies, which target a molecule found only in colorectal cancer cells, to the particles. Once bound, the nanoparticles are engulfed by the cancer... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=3346426 Tue, 09 Mar 2010 00:00:00 +0100 3346426 http://www.medworm.com/index.php?rid=3163749&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2FGAy4FGogVGw%2F J.P. Morgan is hosting its big drug-industry conference this week in San Francisco. Here are a couple tidbits from the first few days: Sales of the multiple sclerosis drug Tysabri topped $1 billion last year, Biogen Idec said today, and the number of patients taking the drug neared 50,000. On the one hand, that’s notable, given that the drug (which Biogen co-markets with Elan) was pulled from the market in 2005 because of safety concerns. On the other hand, Biogen recently said its CEO will step down later this year, a move that Dow Jones Newswires said was linked in part to concerns about Tysabri’s growth trajectory. The CEO, James Mullen, will be speaking at the conference at 4:30 Pacific time today. You can tune in online. Dendreon now has about $600 million in cash, which ... WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=3163749 Tue, 12 Jan 2010 16:43:32 +0100 3163749 http://www.medworm.com/index.php?rid=2898901&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F006634.html Scientists have begun doing complete genome sequencing of tumor cells from cancer patients. Scientists have sequenced the genomes of two tumors from the same breast cancer patient--a primary tumor and... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=2898901 Thu, 15 Oct 2009 23:00:00 +0100 2898901 http://www.medworm.com/index.php?rid=2645277&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2Fx3FhTBPc50E%2F Amgen may want to avoid the “carpet-bombing approach” to selling its new osteoporesis drug denosumab, but it is upping its sales firepower by partnering with pharmaceutical giant GlaxoSmithKline to market the therapy, the companies announced today. The biotech had said last year it was dropping the approach of fielding as many sales reps as possible to tout a drug, calling that an “outdated” model. In the agreement today, Glaxo will pay Amgen $120 million plus royalties to jointly market denosumab in Europe, Australia, New Zealand and Mexico. Glaxo will take over the commercializing of the therapy in all other countries where Amgen doesn’t currently have a presence, including emerging market nations like China and India. “We are optimistic about our fina... WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=2645277 Mon, 27 Jul 2009 21:26:08 +0100 2645277 http://www.medworm.com/index.php?rid=2634371&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2FtmVVOEGYosw%2F There’s plenty of drug-industry zeitgeist crammed into the news that Bristol-Myers Squibb is paying $2.1 billion to buy Medarex. On one side of the equation is Bristol, an old-line pharma company sitting on a lot of cash ($8.1 billion as of the end of the second quarter, according to Bristol’s latest earnings report this morning) and facing the generic competition for its blockbuster Plavix in a couple of years. On the other side is Medarex, a company with two of the most desirable traits in the business: a promising cancer medicine in late-stage testing, and the know-how to develop biotech drugs. Everybody thinks biotech is the wave of the future; cancer drugs command high prices and are seen to meet unmet medical needs, which helps a lot in winning FDA approval. In typical fa... WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=2634371 Thu, 23 Jul 2009 13:43:54 +0100 2634371 http://www.medworm.com/index.php?rid=2447467&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2F3NCxKiWT8U8%2F As the era of targeted cancer drugs has matured, it’s become clear that any single drug stands little chance of keeping cancer in check for an extended period of time in large numbers of patients. So researchers have begun testing combinations of targeted drugs in hopes that a cocktail will prove more effective. This approach has proven successful with traditional chemotherapy, which is often given in multi-drug cocktails. Now Merck and AstraZeneca are pushing the idea further, by pairing two targeted cancer drugs early in development, before either has been clearly proven on its own. The companies will announce today that they will team up to test the drugs, which block two different signaling pathways that are important to the growth of many different types of cancers. Here’s... WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=2447467 Mon, 01 Jun 2009 12:52:05 +0100 2447467 http://www.medworm.com/index.php?rid=2416829&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F006209.html Our genome is coded as DNA. But it gets translated into RNA which serves a variety of roles including as regulatory molecules. Naturally occurring silencing RNAs (siRNAs) are short RNA... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=2416829 Mon, 18 May 2009 04:00:00 +0100 2416829 http://www.medworm.com/index.php?rid=2375873&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2FUwJJKspuIFw%2F Dendreon’s gyrations continue: The biotech company’s shares surged this morning after a sudden plunge yesterday as Dendreon was to about to announce details of its latest Provenge study. The share price more than doubled to $25.42 in morning trading. This comes after the shares’ roller-coaster ride yesterday, in which they hit a 52-week high of $25, then plunged more than $10 in about 30 seconds of vigorous trading before trading was halted for news. The company’s presentation of data on its prostate-cancer treatment Provenge, for which Dendreon is seeking FDA approval, was well received on Wall Street. The company, whose share price has jumped up and down over the past couple of years based on news about Provenge, said the drug prolonged the lives of advanced prost... WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=2375873 Wed, 29 Apr 2009 15:28:11 +0100 2375873 http://www.medworm.com/index.php?rid=2364974&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F006153.html An informative article in the New York Times describes the rather slow progress of attempts to cure cancer. Cancer has always been an expensive priority. Since the war on cancer... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=2364974 Fri, 24 Apr 2009 04:00:00 +0100 2364974 http://www.medworm.com/index.php?rid=2356895&cid=t_112091_87_f&fid=36224&url=http%3A%2F%2Ffeeds.wsjonline.com%2F%7Er%2Fwsj%2Fhealth%2Ffeed%2F%7E3%2FdicgQ-yHYLU%2F That’s a question being asked as investors digest the results of a closely watched study of Avastin in colon cancer. Roche said today that a study of the drug, which was originally developed by Genentech, failed to meet its main goal of preventing colon cancer from returning in patients in the early stages of the disease following surgical removal of the cancer. Avastin is already approved for several late-stage cancers, including colon. A couple of years back, one investment house said the question of whether Avastin works in this early-stage context was “mother of all binary events.” Regulatory approval for an early role could mean billions more in sales. The study’s result is a buzzkill in the wake of Roche’s success in finally winning its protracted takeo... WSJ.com: Health Blog blogs http://www.medworm.com/rss/comments.php?id=2356895 Wed, 22 Apr 2009 12:55:35 +0100 2356895 http://www.medworm.com/index.php?rid=2104519&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F005877.html Gene therapy can activate immune cells to move in on a cancerous growth in the brain. Scientists seeking to harness the power of the immune system to eradicate brain tumors... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=2104519 Thu, 15 Jan 2009 05:00:00 +0100 2104519 http://www.medworm.com/index.php?rid=2035627&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F005789.html Most cancers kill because they metastasize by traveling in the bloodstream, landing in other parts of the body, and then growing in each of these other locations. If cancer cells... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=2035627 Sat, 13 Dec 2008 05:00:00 +0100 2035627 http://www.medworm.com/index.php?rid=1575437&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F005331.html A chip can measure tumor cell blood concentrations and detect drug resistance mutations for circulating cancer cells. Massachusetts General Hospital (MGH) investigators have shown that an MGH-developed, microchip-based device that... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=1575437 Thu, 03 Jul 2008 04:00:00 +0100 1575437 http://www.medworm.com/index.php?rid=1492083&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F005247.html More evidence that chronic inflammation kills: Chronic inflammation of the intestine or stomach can damage DNA, increasing the risk of cancer, MIT scientists have confirmed. The researchers published evidence of... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=1492083 Tue, 03 Jun 2008 04:00:00 +0100 1492083 http://www.medworm.com/index.php?rid=1477938&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F005232.html A stem cell therapy that deliver a tumor suppressing gene showed some benefit in phase III clinical trials. HOUSTON - A gene therapy invented at The University of Texas M.... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=1477938 Thu, 29 May 2008 04:00:00 +0100 1477938 http://www.medworm.com/index.php?rid=889614&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F004607.html At the the third conference for Strategies for Engineered Negligible Senescence (SENS) Dr. Zheng Cui of Wake Forest University reported on impressive progress of his research team toward use of... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=889614 Thu, 20 Sep 2007 04:00:00 +0100 889614 http://www.medworm.com/index.php?rid=823018&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F004529.html Angiogenesis inhibitors work against cancer by blocking the development of new blood vessels into tumors so that tumors can't grow. The hope with angiogenesis inhibitors is that they will have... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=823018 Sun, 26 Aug 2007 04:00:00 +0100 823018 http://www.medworm.com/index.php?rid=781347&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F004456.html Currently a diagnosis of pancreatic cancer is almost always a death sentence. Pancreatic cancer causes little or no symptoms until it has spread and mutated so much that it can't... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=781347 Mon, 06 Aug 2007 04:00:00 +0100 781347 http://www.medworm.com/index.php?rid=733664&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F004384.html Cancer-causing genetic mutations are best fixed with new genetic programming. A molecularly engineered therapy selectively embeds a gene in pancreatic cancer that shrinks or eradicates tumors, inhibits metastasis, and prolongs... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=733664 Thu, 12 Jul 2007 04:00:00 +0100 733664 http://www.medworm.com/index.php?rid=682830&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F004333.html Stem cells help early stage cancer growth by creating blood vessels. Cold Spring Harbor, N.Y. -- Cold Spring Harbor Laboratory (CSHL) researchers led by Daniel Nolan and Assistant Professor Vivek... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=682830 Mon, 18 Jun 2007 04:00:00 +0100 682830 http://www.medworm.com/index.php?rid=543922&cid=t_112091_87_f&fid=34902&url=http%3A%2F%2Fwww.futurepundit.com%2Farchives%2F004184.html Some new research demonstrates how puzzling out the genetic mechanisms of cancer spread points in the direction of useful therapies. Studies of human tumor cells implanted in mice have shown... (Source: FuturePundit) FuturePundit blogs http://www.medworm.com/rss/comments.php?id=543922 Sat, 14 Apr 2007 04:00:00 +0100 543922